Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles

Antitumor activity of a folate receptor-targeted immunoglobulin G-doxorubicin conjugate

“…20 These loading strategies normally resulted in uneven particle sizes ranging from 150 nm to 500 nm and instability in plasma. 20,21 FA-PEG conjugation may prevent the aggregation of IgG proteins and thus ensure the even distribution of particle sizes. On the other hand, FA-PEG-IgG is expected to show ADCC effect in mice or other mammalian animals.…”

Nanoparticle-Based Brain Targeted Delivery Systems

“…Nanoparticles, when entering systemic circulation, are commonly surrounded by a protein "coat, " known as a corona, most commonly composed of albumin [13]. Studies have shown that albumin-and albumin-coated nanoparticles ( Figure 1B) are able to cross the BBB [14,15] and are able to release doxorubicin in in vitro neuroblastoma cell models [15].…”

In vitro and biodistribution examinations of Tc-99m-labelled doxorubicin-loaded nanoparticles

“…Doxorubicin was quantified by UV (250 nm), and the retention time was about 12 min [4]. Non-adsorbed doxorubicin quota was followed up 1 and 24 hours and 7 days after preparation.…”

“…In cancer therapy doxorubicin is a frequently used antineoplastic agent, but in clinical applications this anti-cancer drug is limited due to its high cardiotoxicity [2,3]. A promising solution to decrease cardiotoxicity could be binding doxorubicin to a drug delivery nanoparticle system [4].…”

“…Original the enhanced permeation and retention effect (EPR effect, [13]) that results from the properly selected particle-size distribution, and secondly, elimination of the multidrug resistance in more cancer cell lines [14]. Several methods have been described for bounding drugs to nanoparticulate systems, such as surface attachment of drugs to nanoparticles or polymers [6,15], adsorption to the preformed carrier system, and incorporation into the particle matrix during colloid preparation [4]. While simple adsorption to preformed carrier nanoparticles could lead to the early desorption of targeting ligand, incorporation protects drug-loaded particles from early drug loss, inactivation, or degradation during storage and after administration [4].…”